Vanda Pharmaceuticals(US:VNDA) Prnewswire·2025-02-13 21:01Core Insights - Vanda Pharmaceuticals reported strong revenue growth driven by its psychiatry portfolio, particularly Fanapt, Hetlioz, and Ponvory, with expectations for continued growth in 2025 and beyond [2][5][14] - The company has several key product applications pending, including Bysanti for bipolar disorder and schizophrenia, and Tradipitant for motion sickness, which are expected to contribute to future revenue growth [2][5][9] Financial Highlights - Q4 2024 total revenues reached $53.2 million, a 17% increase compared to Q4 2023 [5][6] - Full year 2024 total revenues were $198.8 million, a 3% increase compared to 2023 [5][6] - Fanapt net product sales in Q4 2024 were $26.6 million, an 18% increase from Q4 2023 [5][6] - The company expects full year 2025 revenues to grow to between $210 million and $250 million [5][14] Operational Highlights - Vanda's psychiatry portfolio is projected to exceed $750 million in revenue by 2030 [5][14] - The company initiated a Phase III program for the long-acting injectable formulation of Fanapt in Q4 2024 [11] - Vanda's acquisition of Ponvory was completed on December 7, 2023, and its commercial launch began in Q3 2024 [6][11] Key Regulatory Milestones - The NDA for Tradipitant for motion sickness was submitted in Q4 2024, with potential approval expected in 2025 [11][12] - Bysanti's NDA for bipolar disorder and schizophrenia is expected to be submitted in Q1 2025 [5][11] - The MAA for HETLIOZ for Smith-Magenis syndrome was submitted in Q4 2024 [5][11] Cash Position - As of December 31, 2024, Vanda had cash, cash equivalents, and marketable securities totaling $374.6 million, a decrease of $1.6 million from the previous quarter [6][11]